Indiana University School of Medicine cancer researchers have identified a potential way to use existing, accessible drugs to combat juvenile myelomonocytic leukemia (JMML) by targeting a specific inflammatory pathway.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.